Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024PR Newswire • 17 days ago
Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at AACR Annual Meeting 2024 Elevation Oncology Presents Preclinical Proof-of-Concept Data for HER3-ADC Program at...
Share to Feed
In this piece, we will take a look at the 13 hot stocks to invest in according to Wall Street analysts. If you want to skip our overview of the stock market and the latest news, then you can skip...
Elevation Oncology, Inc. (NASDAQ:ELEV Get Free Report) saw a significant decrease in short interest in February. As of February 29th, there was short interest totalling 3,610,000 shares, a...
JMP Securities reissued their market outperform rating on shares of Elevation Oncology (NASDAQ:ELEV Free Report) in a research report report published on Thursday, Benzinga reports. JMP...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Adaptimmune Therapeutics (ADAP Research Report), Elevation Oncology...
Elevation Oncology (NASDAQ:ELEV Free Report) had its price objective lifted by Wedbush from $5.00 to $8.00 in a research note issued to investors on Thursday, Benzinga reports. They currently...
Elevation Oncology, Inc. (NASDAQ:ELEV Free Report) Research analysts at HC Wainwright issued their Q4 2025 earnings estimates for Elevation Oncology in a research report issued to...
Elevation Oncology (NASDAQ:ELEV Get Free Report)s stock had its market outperform rating reissued by analysts at JMP Securities in a research report issued on Thursday...
Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Business Achievements Elevation Oncology Reports Fourth Quarter and Full Year 2023 Financial...
Elevation Oncology GAAP EPS of -$0.19...